Healthcare Professional and Patient Surveys to Assess the Effectiveness of Risk Minimisation Measures for Concentrated Insulin Lispro (Humalog 200 units/ml KwikPen; Liprolog 200 units/ml KwikPen) (F3Z-MC-B019)

First published 10/05/2016

Last updated 26/09/2017

EU PAS number:

EUPAS13422

Study

Finalised

Documents

Study protocol

Initial protocol

F3Z-MC-B019_EU-PAS-Registered

English (494.57 KB - PDF) View document

Study results

F3Z-MC-B019_Final_Report_EUPAS_Registered

English (1020.41 KB - PDF) View document

Study report

Other information

Secondary tabs